AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 62 min read$SGHT

Bauerlein Alison sold $130K of SGHT

Bauerlein Alison (Chief Operating Officer) sold 24,184 shares of Sight Sciences, Inc. (SGHT) at $5.36 ($0.13M total) on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bauerlein Alison
Published Jul 6, 2026, 11:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 11:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$SGHT
Neutral
medium confidence
Mentioned
$SGHT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SGHTNeutralLow
01

Why it matters

The disclosure provides a fresh, timestamped datapoint on insider activity but does not change the company’s fundamentals based on the text provided.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a sustained repricing without additional news.

03

What to watch

The filing does not include any new company-specific performance, trial, regulatory, or financing information—so traders should avoid over-weighting the sale versus other catalysts.

Relevance 3/10Novelty 4/10Timing: SEC Form 4 filed July 6 for a July 2 insider sale.

Background

The article is an SEC Form 4 insider transaction: COO Bauerlein Alison sold shares under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$SGHTNeutralMedium confidence
Context

Sight Sciences disclosed a COO open-market sale of 24,184 shares at $5.36 on a 10b5-1 plan, filed July 6.

Expected impact

Likely limited/short-lived impact; any reaction should fade unless accompanied by other company-specific catalysts.

Evidence & confidence

Form 4 is a primary filing and is time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan and lacks accompanying operational/financial disclosures.

Market effects

Sector

No clear read-across to the broader biotech/healthcare sector from a single routine 10b5-1 sale.

Regional

No material regional market implications indicated.

Global

No global catalyst or cross-border transaction described.

Counterpoint

What could challenge this read

Because the sale is on a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Sight Sciences, Inc.

    Subject of the Form 4 insider transaction; ticker SGHT.

  • insider
    Alison Bauerlein

    Chief Operating Officer who executed the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SGHT insider trading history →

Related articles

AUG 20
$SGHTHighAI 8/10

FDA Broadens ‘Indications for Use’ for Sight Sciences’ TearCare System

Sight Sciences (SGHT) announced FDA expanded the TearCare System's use to improve meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first treatment indicated for this purpose, according to the company. The update also includes optional debridement, enhancing its approach to treating the condition. SGHT reported Q2 2026 revenue growth and updated its full-year guidance earlier this month.

visionmonday.com2 min
AUG 19
$SGHTMedAI 8/10

Sight Sciences, Inc.: TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences (SGHT) announced FDA approval for its TearCare System to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). This makes TearCare the first and only treatment indicated for this purpose, expanding its market potential. The company's CEO and a medical expert highlighted the significance of this milestone in dry eye disease treatment.

finanznachrichten.de2 min
AUG 19
$SGHTHighAI 8/10

TearCare is the first and only treatment indicated to improve gland function in dry-eye patients

Sight Sciences (SGHT) announced that the FDA expanded the TearCare System's indication to include improving meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first and only treatment with this indication, effective August 18, 2026. The update also incorporates optional debridement into the system's treatment approach.

stocktitan.net2 min
AUG 19
$SGHTMedAI 8/10

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences (SGHT) announced FDA expanded approval for its TearCare System, now the only treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). The update includes optional debridement, enhancing its comprehensive approach to treating MGD. According to the company, this milestone reflects its commitment to advancing dry eye disease treatment.

globenewswire.com2 min
AUG 13
$SGHTMedAI 8/10

Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences (SGHT) reported Q2 2026 revenue of $23.4M, up 20% y/y, driven by Interventional Glaucoma ($20.7M) and Interventional Dry Eye ($2.7M). Gross margin rose to 91% from 85%. Net loss was $4.4M. FY2026 revenue guidance raised to $88M-$92M; adjusted opex guidance lowered to $92M-$94M. Alcon patent appeal remains pending.

fool.com7 min